AR and metastatic prostate carcinoma: Given the diversity in molecular phenotypes observed in advanced metastatic prostate cancer, we divided tumors into four clinically relevant molecular subgroups based on the expression of androgen receptor (AR) signaling or neuroendocrine (NE) marker described previously (Fig. 3; ref. 13).